



**KOLINPHARMA®**  
LEADER TO HEALTH

**KOLINPHARMA®: CONFIRMED THE CLINICAL EFFECTIVENESS OF THE FOOD SUPPLEMENT  
XINEPA® FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES**

*The clinical study conducted at the Hospital Umberto I in Rome is referred to Xinepa® effects, patented nutraceutical product of the Company for the treatment of peripheral neuropathies which affect 7-8% of European population over 55*

*Milan, March 20<sup>th</sup> 2018*

*KOLINPHARMA® SPA, Innovative SME operating in nutraceutical sector, publishes the results of the clinical study conducted on the food supplement Xinepa® aimed at evaluating its effectiveness in combination with very low frequency electromagnetic waves for the treatment of peripheral neuropathies, which in Europe affect the 7-8% of the population over 55.*

*The results will be published on the magazine The Journal of Physical Therapy Science.*

*The market of products to treat the skeleton-motor area, the peripheral neuropathies are part of, according to Federsalus' data (updated as of December 2017), is worth about € 125.3 million in Italy and it is estimated growing by 5% compared to 2016.*

*"The empirical evidence of this study conducted at the Hospital Umberto I in Rome affirms the effectiveness of Xinepa® to treat peripheral neuropathies. Moreover, with this study it has been confirmed the peculiarity of KOLINPHARMA's approach, that stands out in the nutraceutical market thanks to the constant research of scientific evidences, to demonstrate the effectiveness of our products based on active substances" – declared the BoD's Chairwoman, Rita Paola Petrelli.*

*The study was referred to patients afflicted with the carpal tunnel syndrome, widespread peripheral neuropathy, that were divided into two groups: the first one was treated both with Xinepa®, twice a day for a month, and with very low frequency electromagnetic waves (3 times a week for 12 sessions); whereas the second group was treated with a placebo and very low frequency electromagnetic waves. Patients have been valued before the beginning of the treatment (time 0), at the end of it (time 1) and after 3 months (time 2). In the first group of patients who took Xinepa®, there were some statistically significant improvements in terms of pain and functionalities, both at the end of the treatment, after a month, and after 3 months. In the second group treated with placebo and very low frequency electromagnetic waves, the improvement was registered at the end of the treatment, but there was not after 3 months. The carpal tunnel treatment with Xinepa®, in association with very low frequency electromagnetic waves, demonstrated that the use of the food supplement Xinepa® gives the chance to have clinically significant results, reducing the pain and facilitating the functional recover over time, even 3 months after the treatment.*

*Xinepa® is the food supplement recommended for mechanical peripheral neuropathies, post-traumatic or by compression, based on alpha lipoic acid, N-acetil-carnitine, curcuma, vitamins B, E and C. The vitamins B1, B2,*



KOLINPHARMA®

LEADER TO HEALTH

**B6 and B12 contribute to proper functioning of the nervous system and energy metabolism; moreover, vitamins B2, B6 and B12 are very useful in case of tiredness and fatigue.**

This press release is available online on our corporate website [www.kolinpharma.com](http://www.kolinpharma.com), in the section Investor Relations > Financial Press Releases.

\*\*\*

*KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 63 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.*

**Contacts**

IR TOP Consulting S.r.l  
Capital Markets & Investor Relations  
Floriana Vitale, Domenico Gentile  
[f.vitale@irtop.com](mailto:f.vitale@irtop.com), [d.gentile@irtop.com](mailto:d.gentile@irtop.com)  
Via C. Cantù, 1 - 20123 Milan  
Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd.  
Nominated Adviser (NOMAD)  
Francesca Martino  
[fmartino@enventcapitalmarkets.co.uk](mailto:fmartino@enventcapitalmarkets.co.uk)  
42 Berkeley Square - London W1J 5AW Italian  
Branch, via Barberini n. 95 - 00187 Rome  
Tel.: +39 06 896841 Fax: +39 06 89684155

